Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
February 25, 2021
Earnings Call Speaker Segments
Executive
executiveJake Elguicze, who serves as Treasurer and VP of Investor Relations, then Liam Kelly, our Chairman, President, and Chief Executive Officer, followed by Thomas Powell, Executive Vice President and Chief Financial Officer.
Jake Elguicze
executiveGood morning, everyone, and thank you for joining us on the Teleflex Incorporated Fourth Quarter 2020 Earnings Conference Call. You can find the press release and accompanying slides on our website, www.teleflex.com. As a quick reminder, this call is being webcast on our site, and a replay will be available by calling 855 to 859 to 2056, or if you're dialing internationally, 404 to 537 to 3406, with passcode 8789956. With us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom will deliver prepared remarks, and following that, we'll take your questions. At the start, please note that certain topics we'll cover on this call include predictions about upcoming occurrences, which are described in our slide deck. We need to warn everyone that these remarks are indeed anticipatory by nature and carry exposure to dangers and unknowns, so real outcomes or happenings could end up substantially different. Elements that might lead to genuine outcomes or occurrences diverging substantially encompass, though aren't restricted to, those mentioned in the release we issued today, plus the documents we submit to the SEC, such as our Form 10-K, reachable through our site. Also on today's call, you'll hear our leadership discuss how COVID-19 is estimated to have helped or hurt our business in the fourth quarter and across all of 2020. They'll also share remarks about how business performed within the first quarter of 2021. We're offering these comments so investors gain extra perspective on emerging patterns, and we may not give this kind of disclosure again in later quarters. Having said that, I'll hand things over to Liam now.
Liam Kelly
executiveThank you, Jake, and good morning to all of you. It's a pleasure to be speaking with you today. Before diving into the specifics of how we performed this quarter, I want to express once more my condolences to those affected by COVID-19, along with heartfelt gratitude to every healthcare worker who keeps risking their own safety in the fight against this virus day in and day out. I'd also like to pause and acknowledge the Teleflex team members worldwide once again. The past year has brought plenty of difficulties, yet our people have performed remarkably in supporting customers and patients across the globe, pushing past barriers to produce and deliver our products to those who depend on them most. Thank you; now let's move on to our results. Given the unpredictable conditions in which we operate, we're satisfied with how we did in the fourth quarter, since our business outperformed what we had anticipated and conditions kept getting better throughout many of our product categories and geographies; we observed sequential gains that beat expectations moving from quarter 2 into quarter 3 and from quarter 3 into quarter 4. Even though COVID-19 infections climbed during the fourth quarter, the rebound in our business was driven by the product lines that COVID-19 had hurt the most at the outset — namely our Interventional Urology, Interventional Access and Surgical businesses — along with ongoing strength in our Vascular Access and other product categories. Regionally speaking, we benefited from strength in the Americas, positive growth in EMEA, and improving trends in Asia. Fourth quarter revenues came to $711.2 million, an increase of 2.3% on a constant currency basis versus the same period a year ago. Growth during the quarter benefited from 2 extra selling days, which we estimate added roughly 3% points. If we set aside the effect of those extra selling days, we estimate our constant currency revenues fell by about 1%. These adjusted declines show continued recovery progress compared with the 4% decline we saw in the third quarter of the year and the 12% decline we saw in the second quarter of the year, and they came in ahead of what we had expected back when we held the third quarter earnings call. During the fourth quarter, we estimate that COVID-19-related headwinds produced a net negative impact of roughly $61 million, or approximately 9%. Normalizing for that negative impact, we estimate our underlying business grew by about 11% on a constant currency basis, or 8% after normalizing for the selling day impact. Beyond the continued sequential gains in our constant currency revenue performance during Q4, we also achieved significant sequential improvement in our adjusted gross and operating margins relative to the second and third quarters of the year; that improvement lifted adjusted earnings per share, which came in above our internal expectations. Finally, I'm pleased to share that on December 28th, we completed the acquisition of Z-Medica, a market leader in hemostatic products. We're happy that we can put capital to work behind a product lineup that stands apart, builds on Teleflex's current call points, and immediately boosts our revenue growth rates along with our adjusted gross margin, operating margin, and adjusted earnings per share. Now moving into a closer look at what happened in quarter four. Like I said earlier. In Q4, revenue rose 2.3% in constant currency terms and 4.4% as reported. The gain came primarily from our Vascular Access Portfolio, which enjoyed certain favorable conditions tied to COVID-related buying, plus solid mid-single-digit expansion in Interventional Urology and our other segment. Looking at margins, adjusted gross margin came in at 58% and adjusted operating margin at 26.6%. That meant declines versus the same period last year of 120 basis points on the gross margin side and 50 basis points on the operating margin side. That said, measured sequentially, it marked a gain of AZ and 150 basis points respectively over quarter three figures. On the bottom line, adjusted earnings per share came to $3.25. Taken together, how we performed financially this quarter shows the enduring resilience of our diversified worldwide product portfolio, and it leaves us confident that we can hit our long-term financial targets once COVID-19 is behind us. Let's shift now to talking about our quarterly revenue trends, all of which will be given in constant currency terms. The Americas posted fourth quarter revenues of $419.5 million, up 5% versus the equivalent period a year ago. Within the Americas, growth came from Vascular Access and respiratory products, both of which experienced heightened demand because of COVID. Beyond that, Interventional Urology contributed strongly, since UroLift remains the procedure recovering fastest for us. Still, there were offsets from decreases in other product categories; by our estimate, the Americas would have expanded roughly 12% if not for the effects COVID-19 had on that region. EMEA brought in fourth quarter revenues of $161.4 million, which works out to growth of 4.1%. In that quarter, EMEA got a lift from a one-time order for tracheostomy products as well as from the additional selling days, and together those more than made up for the roughly 1% of COVID headwinds we estimate. Now on to Asia. Fourth quarter revenues came to $78.6 million, a decline of 7.2%; even so, we estimate that absent the impact of COVID-19, we would have posted positive constant currency revenue growth in the mid-single digits. Also in quarter four, we completed the transition of a distributor in Japan. Once you adjust for both COVID and that distributor change, growth for the region would have landed in the mid to high single-digit range. Finally, our OEM business posted fourth quarter revenues of $57.7 million, down 6.9% on a constant currency basis. Just as we expected going into quarter four, our OEM business felt a COVID-related impact that was in line with what our other businesses experienced. Those of you who follow Teleflex know that our OEM segment provides device makers with intricate catheters and surgical sutures, and the fourth-quarter effect shows lower order volumes from those customers, whose business depends on procedures that are not emergent. If you set aside what COVID-19 did, this business expanded by about 31%, and that figure carries a roughly 13% lift from buying HPC. Regarding HPC, I'm happy to say our integration work continues right on schedule. Now let's turn to how our revenue broke down across worldwide product categories. Beginning with Vascular Access, revenue for the fourth quarter rose 16%, reaching $182.5 million. Our estimate is that COVID-19 added about 5% to the growth rates of our vascular products in that quarter. The main growth contributors were PICC, up approximately 20%, CVCs, up approximately 16%, and EZ-IO, which climbed approximately 14%. Shifting to Interventional Access, fourth-quarter revenue came in at $106.7 million, a decline of 6.9% from the same period a year earlier. That drop mostly stemmed from slower recovery of certain non-emergent procedures owing to COVID 19, plus the adverse effects of a catheter recall and a distributor conversion in Japan, both of which got underway in the prior quarter.
Liam Kelly
executiveWe figure the recall plus the distributor problem set our business back by roughly $3 million. We anticipate the recall's effect will keep dragging on through the coming few quarters, since we don't expect to have this product back in the market before September of this year, whereas the distributor inventory drag ought to flip around and give us a slight lift in 2021. If we adjust for what COVID did as well as those headwinds just mentioned, we calculate that underlying growth landed in the high single digits, in line with the long-term growth outlook we hold for the segment; on top of that, we're happy that Manta posted 33% growth worldwide in quarter four. Now on to Anesthesia, where revenue came in at $86.1 million, down 2.1% from the prior-year period. That decrease stemmed from weaker sales of laryngeal masks and endotracheal tube products; we figure COVID produced roughly a 1% negative effect in the quarter, which suggests performance was flattish on an underlying basis. Because we completed the Z-Medica acquisition only days before year-end, its effect on quarter four results was immaterial. Moving to Surgical. Revenues fell 5.7% to $92.3 million, pulled down by weaker sales in our ligation portfolio. We estimate a 9% COVID headwind across quarter 4, which points to recovery relative to the estimated 13% COVID headwind in quarter three. On to Interventional Urology. Quarter four revenue rose 5.3% to $93.9 million, a new high watermark for revenue dollars in any single quarter. Compared with the prior year, this business ran into a tough growth comparison, yet sequentially it was up 15% against quarter three. We estimate a COVID-19 related headwind of approximately 28% during quarter four. Despite that sizable headwind to our growth in quarter four, we're pleased with how this business unit is recovering and are also happy with what the national DTC campaign has delivered, which is beating our expectations. Furthermore, we're encouraged that we trained about 130 new urologists in quarter four, which puts us at a cadence matching what we expected before COVID and stands as a positive leading indicator for growth ahead; and last, our other category, made up of our respiratory and urology care products, rose 6.1% to total $98.1 million; we estimate the quarter's growth came partly from higher demand for certain humidification and breathing products tied to COVID-19, mainly in the Americas. That wraps up my remarks on quarter four revenue performance. Turning to a few recent clinical and commercial updates. Beginning with UroLift, the response to our national DTC campaign is beating our expectations. DTC's strategic role matters because roughly half of the 12 million men receiving treatment for BPH believe prescription medications are their only option. All told, we regard the pilot national DTC as a successful campaign. Key statistics include a doubling of brand awareness among men age 45 and higher post campaign versus pre-campaign levels. During the campaign, visits to UroLift.com rose by roughly 150%, and direct response figures came in well above what we had projected internally. In addition, Google search trends show a meaningful, lasting lift tied to the campaign. Because of that, we plan to keep the national DTC program going in 2021 and afterward. Now on to UroLift as well; the market acceptance test is finished, and feedback has been positive from over 100 procedures performed by 20 urologists. A full controlled launch has started. It is controlled because COVID-19 has restricted access. That approach keeps us from hurting the growth recovery with a broader rollout that starts in the back half of 2021. We stay confident that conversion to UL2 will happen gradually, and we still anticipate meaningful margin expansion once the revenue base has fully converted. On Japan, a reimbursement decision in 2021 remains on schedule, and we see the roughly $2 billion addressable market as an added growth driver and a favorable catalyst for the foreseeable future. Taken together — nationwide DTC, the Japan rollout, and the UL2 launch — we have several drivers to create momentum as we work to extend our leadership position in BPH. Moving to the next slide on key clinical updates. A comparative analysis of sexual function outcomes from UroLift studies and the Medical Therapy of prosthetic symptoms trial was published recently in the peer-reviewed journal European Urology Focus. That comparison shows UroLift beats BPH medical therapy when it comes to preserving erectile and ejaculatory function along with sexual satisfaction. Equally important, the study disputes the notion that medical therapy represents the most conservative treatment choice for BPH. In time, we think additional clinical research such as this publication will lead to UroLift being viewed as a first-line therapy for treating BPH. Now an update on Interventional Access. As for the CTO-PCI study we discussed on our Q2 earnings call, I am glad to report that enrollment has been completed. It is a prospective, single-arm IDE study involving 150 patients at 13 sites, designed to assess how the full range of Teleflex coronary guidewires and specialty catheters performs in chronic total occlusion percutaneous coronary intervention procedures, the most demanding PCI setting. After the study results are finalized, we expect updated labeling for our Guidewire and Specialty Catheter products, which could cover an estimated 100,000 CTO-PCI procedures. All in all, we keep investing in clinical and commercial catalysts that support our upper single-digit revenue growth goals in a normalized environment. Finally, on EZPlas. I am pleased to tell the investment community that we submitted our BLA to the FDA successfully in late January. We just completed a market assessment update and continue to see a $100 million initial market opportunity for EZPlas. Our confidence keeps growing in our ability to capture this commercial opportunity, with revenue probably ramping in early 2022. Beyond that, we see possible revenue synergies alongside Z-Medica by making use of their sales representatives and our own channel strength in healthcare and government call points, which might contribute beyond what we have built into our baseline expectations. That leads me to an update on the most recent acquisition we made. On December 28th, we closed our purchase of Z-Medica, a top manufacturer in the hemostatic products industry, and this transaction fits the classic Teleflex pattern and is strategically very well aligned. Those who follow Teleflex know our intent is to put money into innovative products and technologies capable of meaningfully improving clinical efficacy along with patient safety and comfort, cutting complications, and bringing down the total cost of care. Because their products are differentiated and their end markets appealing, we look at the Z-Medica purchase much as we did Vidacare a few years back. From the time we bought Vidacare in 2013, sales have grown to more than twice their former level and continue expanding at a healthy double-digit rate. One point of difference: Z-Medica is growing into a $600 million addressable market, whereas Vidacare's addressable market stood nearer to $250 million. Now, on to our long-range financial targets.
Liam Kelly
executiveThe Z-Medica acquisition just strengthens our capacity to reach those targets, and we're still dedicated to achieving constant currency revenue growth each year of no less than 6% to 7%, along with adjusted gross and operating margins of 60% to 61% and 30% to 31% once conditions become more normalized again. We're planning to host an Analyst Day in the fall of this year, and at that point we intend to share updated long-term financial goals and timetables. That wraps up my prepared remarks. At this time, I'd like to hand the call over to Tom so he can give a more detailed review of our fourth quarter financial results. Tom?
Thomas Powell
executiveThank you, Liam, and hello everyone on this call. Since revenue results were already covered earlier, I'll pick up with the gross profit line. Adjusted gross margin came in at 58% for the quarter, which represents a 120 basis point decline from the same period last year. This margin contraction was mainly driven by COVID-related factors, such as an unfavorable product mix, elevated manufacturing costs, and a modest foreign exchange headwind. All told, we estimate COVID had an adverse effect of roughly $44 million on adjusted gross profit during the quarter; we've kept a tight rein on discretionary spending, which partly offsets the revenue and gross profit shortfall caused by COVID. Thanks to those efforts, we estimate fourth quarter operating expenses came down by about $13 million. Across all of 2020, we held OpEx lower by an estimated $78 million. Operating margin for the fourth quarter stood at 26.6%, a decline of 50 basis points compared with the prior year. Continuing further down the income statement. Net interest expense came to $18.5 million, up 10% from a year earlier, reflecting larger average debt balances than in the prior year period stemming from the HPC and Z-Medica acquisitions. Now on to taxes: our adjusted tax rate for the fourth quarter of 2020 was 10.1%, versus 7.7% in the same period last year. At the bottom line. Fourth quarter adjusted earnings per share slipped modestly to $3.25, down from $3.28 a year ago. This figure includes an estimated COVID drag of roughly $0.55 along with a foreign exchange benefit of approximately $0.05. Now for a few balance sheet and cash flow highlights. Cash flow from operations for 2020 was flat relative to 2019, totaling $437.1 million. We're happy with that result considering the COVID headwinds and the higher contingent consideration payments that ran through cash flow from operations in 2020 versus 2019. On the whole, as 2020 came to a close, our balance sheet is in solid condition. At year-end, cash stood at $375.9 million, compared with $301.1 million as of December 2019. During the year, we put over $750 million to work on external business development opportunities; we'll keep balancing our investments between organic and inorganic initiatives to fuel growth and drive margin expansion, with M&A as our top priority for capital deployment. Including Z-Medica financing, net leverage finished 2020 at 2.98 times, still comfortably under our 4.5 times covenant. Finally, we face no near-term debt maturities of material size. To wrap up, even though 2020 brought a difficult operating environment, the organization adapted fast and executed well; we stay optimistic about the future and expect recovery to begin in the second half of 2021. With that, we're reinstating financial guidance for 2021. To start, I'll lay out a framework of key assumptions behind our financial guidance. Our outlook assumes COVID disruption persists through much of the first half of the year, with the second half much closer to a normal operating environment. Our foundational outlook is built on the idea that healthcare systems will be able to handle COVID surges that come in increments, drawing on lessons from before to prevent broad shutdowns of procedures. It also leaves out any significant changes to regulation, healthcare, or taxes, along with any M&A that might happen later. And on the selling day side, the first quarter will contain 2 fewer days than the same period a year earlier, the 4th quarter will contain one extra day versus the prior-year period, and the second and third quarters will see no change in day counts. For 2021, our projection for constant currency revenue growth is somewhere between 8% and 9.5% measured against 2020. We see our Interventional Access, Surgical and Vascular Access product offerings as major drivers of that constant currency revenue growth in 2021. We also anticipate that our Interventional Urology business will grow by at least 30% relative to 2020 levels. On top of that, Z-Medica should bring in $60 to $70 million of revenue, which works out to roughly 2.5 points of growth. Now on currency. We anticipate that foreign currency exchange rates will provide a tailwind of roughly 2% to revenue growth. Consequently, our as-reported revenue should rise somewhere between 10% in 11.5% versus 2020, which translates to a $1 range spanning $2.791 million to $2.829 million. Next, gross margin. For 2021, we expect adjusted gross margin to rise by 130 to 230 basis points, landing in a range of 8% to 59%. The main driver of gross margin expansion should be a favorable mix of high margin products, chiefly Interventional Urology, plus the Z-Medica acquisition, which contributes roughly 50 basis points to gross margin. Now on to adjusted operating margin. For 2021, we expect adjusted operating margin to climb by 110 to 210 basis points, reaching a range of 26% to 27%. That rise in adjusted operating margin will come from the gross margin expansion, partly offset by the normalization of certain 2020 COVID-related spending reductions, which were temporary by nature, and by further strategic investments into UroLift and Manta. Beyond that, the Z-America acquisition should deliver a modest tailwind to year-over-year operating margin expansion. Because Z-Medica carries a relatively higher OpEx cost structure than Teleflex, the operating margin accretion it brings will fall short of the 50 basis points of gross margin accretion; that brings me to our adjusted earnings per share outlook for 2021; this slide acts as a bridge from our full-year 2020 adjusted EPS results to our full-year 2021 adjusted EPS outlook, starting with the 2020 adjusted EPS of $10.67. From an operating perspective in 2021, we project additional earnings of between $1.58 and $1.66 per share, or an increase of roughly 15%. Our 2021 EPS guidance also rests on the following: Foreign exchange has planned recent spot rates for key currencies including a full-year euro to dollar exchange rate of $1.21. Looking at 2021, we anticipate foreign exchange will give us a tailwind of roughly $0.35. Our current projection is that Z-Medica will add somewhere between $0.21 and $0.26 to adjusted earnings per share in 2021, up from what we initially anticipated, which was a contribution in the range of $0.07 to $0.15. This larger Z-Medica accretion stems from a shift in how we plan to fund the acquisition — we now think it will be accomplished via a mix of borrowings under our revolver plus free cash flow, rather than the bond offer we had previously envisioned. Now on to interest. For 2021, interest expense should come in somewhere between $63 and $65 million. If you back out the incremental financing costs tied to Z-Medica, the decline in interest expense compared to last year should add between $0.17 and $0.19 of earnings accretion. Shifting to taxes. We forecast our adjusted tax rate for 2021 landing in the 13.5% to 14% range, producing an adjusted earnings per share headwind of $0.33 to $0.38. The anticipated rise from last year in the adjusted tax rate comes from a larger expected mix of U.S. taxable income, driven mainly by UroLift growth, along with certain 2020 tax benefits we don't anticipate recurring in 2021. On top of that, we're assuming the 2021 windfall benefit from stock based compensation will be lower than the unusually high level we saw in 2020. We project weighted average shares rising to $47 million for full-year 2021, which creates dilution of about $0.10. Even with a number of headwinds, our adjusted earnings per share guidance of $12.50 to $12.70 is strong, reflecting growth between 17.2% and 19% compared to 2020. Since we expect COVID to keep having an impact into 2021, I want to point out a few things about quarterly expectations. As I said earlier, our outlook assumes COVID will go on disrupting things through the first half of the year, hitting us especially hard in the first quarter. On top of that, the first quarter of 2021 contains a few fewer selling days than 2020 did. Consequently, at the midpoint of our guidance ranges, we expect to deliver roughly 22% of full-year as reported revenue and approximately 19% of our full-year adjusted earnings per share in the first quarter of 2021, and that wraps up my prepared remarks. I'd like to hand the call back to Liam now for closing commentary. Liam?
Liam Kelly
executiveThank you, Tom. To wrap up, our fourth-quarter performance came in strong, with the diversified nature of our portfolio delivering gains over Q2 and Q3 on both revenue and earnings. Setting aside COVID's effects, we find the underlying trends in our business heartening, and although some degree of unpredictability will persist across the coming few quarters, our confidence in executing throughout 2021 remains firm, and we will keep directing our efforts toward supporting hospital clients and collaborating with the stakeholders who matter most to us. The opportunities ahead for our company generate real enthusiasm. A number of revenue catalysts exist for us, among them UroLift, Manta, Z-Medica, PICC, Vidacare, EZPlaz and HPC, just to cite several; we intend to run this business carefully while maintaining our focus on capturing the long-term upside of our worldwide product portfolio. Before I finish, I'd like to express gratitude to the 14,000 team members across the globe who keep producing, shipping and backing the products needed in the battle against COVID-19, and who united in a way that reflects our culture and core values, holding fast to our mission of bettering the health and quality of people's lives. As a company, our position remains strong for generating value on behalf of every stakeholder. That brings my prepared comments to an end. At this point, I'll hand the call back to the operator so we can begin Q&A.
David Lewis
analystThanks, and good morning. I appreciate you taking my question. I've got one about guidance, and then a follow-up for Liam regarding Urology. Tom, this is for you — just a couple of small items on the guidance. Your topline is clearly a bit light versus the Street, but on the bottom line you're bracketing the Street. I assume that's due to FX and Z-Medica. Could you bridge us there a bit, since it certainly reflects some recovery opportunity? And what recovery are you assuming as we move toward March, given we're now at the end of February? Then a quick one from Liam as well.
Thomas Powell
executiveWhen we put together our 2021 plan, we assumed that marketplace levels in the first and second quarter would look somewhat like what we saw in the fourth quarter, and after that we expect recovery to follow starting in the third quarter, returning to what we'd view as more normalized procedure levels in revenue growth rates. And could you maybe remind me of the first part of your question again?
David Lewis
analystI apologize, Tom — you're basically steering under the top end's mark while matching the street down at the bottom, and my read is that FX plus Z-Medica financing explain most of it, though clearly there's a great deal of earnings potential sitting there. I'd just like to see whether you can walk through the bridge a bit and confirm that's right.
Thomas Powell
executiveSure — I'd say that's the correct way to view it, because when you examine the guidance, it does fold in FX and Z-Medica along with several of those other elements we've already discussed.
Liam Kelly
executiveDavid, let me just make one point about the topline guidance if I can. Our approach to that guidance, we believe, was fairly prudent. September feels like quite a while back now, yet at that time we spotted the possible danger posed by rising COVID case counts, which did affect quarter 4, and looking back, that judgment proved right. We were somewhat alone in that position at the time, but by now most of the market has come around to it. In the same way, given the uncertainty that persists, we have been careful in how we think about our 2021 guidance. Expecting a recovery in the back half of the year might strike some as a bit conservative, but I would rather start off conservative, and as you suggest, if it turns out we were too conservative, that ought to affect not just revenue but earnings per share as well, no question.
David Lewis
analystAlright, Tom, the floor is yours.
Thomas Powell
executiveWhen examining what makes up our growth and considering that EPS bridge, the real driver is how well operations are performing. If you take the shifts in interest, taxes, shares, and foreign exchange and group them together, they end up almost canceling each other out for us. And clearly, Z-Medica contributes a 25 cent gain. So when you consider what is behind that, it comes down to the business's core results, while the non-operating pieces roughly net to zero overall.
David Lewis
analystOkay, that's really useful. Then, Liam, returning to the Urology side, specifically NeoTract: the COVID-adjusted figure for Q3 comes in at roughly 30%, which clearly is somewhat below what you recorded in Q2 and Q3. I realize these numbers carry a great deal of COVID-related distortion, yet when I consider that roughly 30% figure for Q4, and also factor in the incremental lift from DTC balancing out the resurgence, how ought I to frame that 30% adjusted figure against the roughly 40% to 45% figures we observed during Q2 and Q3? Just give us a read on the underlying momentum and how you view that business heading into 2021. Many thanks.
Liam Kelly
executiveYour calculation is right. Given COVID's effect, it expanded at 33%, and UroLift's results genuinely made us happy. You need to view it against the backdrop of what took place during Q4, David. We observed fresh COVID variants, we observed cases climbing, we observed procedures being called off, and honestly we were quite pleased that we in fact modestly beat our internal projections for the product. And I think it faced a genuinely difficult comp 2 against the earlier year. If you recall, during Q4 of last year we expanded quite aggressively — I believe it was up 52% in Q4 — so encountering a hard comp, I think that played a role too. And my personal perspective on this is that given cases increasing, I would have anticipated UroLift to fall short of our — . My belief is that it avoided doing so thanks to the DTC offset, which made up for it. So, I think we're sitting in fairly solid shape with UroLift concerning the recovery, and we feel truly confident about where we stand with it.
David Lewis
analystGreat, thanks so much.
Liam Kelly
executiveCheers Mate.
Larry Keusch
analystThanks. Good morning, everyone.
Liam Kelly
executiveGood morning, Larry.
Larry Keusch
analystMorning, Liam. Coming back to UroLift — I realize you already touched on the thinking behind the '21 guide in general, but could you go over again how you're framing the UroLift guide for '21, that 30% plus? What's your view on the pacing there, and what does it bake in for Japan revenues? Then I have a follow-up.
Liam Kelly
executiveAll right. Let's begin with Japan revenue. Larry, Japan contributes very little to the UroLift number in our guide; we still expect a reimbursement decision to come our way as we move through Q2 and Q3, which means we'd be producing revenue in Japan, yet it stays quite small inside the guide we have now. What we'd look for, Larry, and as Tom's prepared remarks made clear regarding the Q1 revenue cadence, is that total company revenue lands at roughly minus 1% to minus 2% in Q1, since case volumes climbed after the January holidays and kept rising through February, and UroLift falls into much the same category. That means the growth we posted in Q4 ought to be somewhat lower in Q1, after which you should witness a steady recovery across Q2, Q3 and Q4. UroLift does face an easier comparison in Q2, though every Medtech company faces an easier comparison in Q2; so the rubber really meets the road, to borrow that phrase, once we reach Q3 and Q4 and start scaling back up — COVID cases ought to be under control by then, the vaccine ought to be distributed by that point, and at that point we should start scaling back up, and given the product was essentially flat year-over-year in 2020, I think getting beyond that 30% growth would also signal 30% growth on 2019 as well, Larry. So beyond 30% growth against 2019.
Larry Keusch
analystAll right, thank you; that's quite useful, and then the other brief item here concerns EZPlas—you restated that market at more than $100 million. And it seems you took another pass at that opportunity and are still landing in that same range. My guess, and tell me if I've got this wrong, is that you're likely viewing this as an FDA clearance in late '21. How do you expect that revenue to begin affecting 2022? How does that unfold? Should we anticipate Military orders possibly arriving unevenly while you build the civilian market simultaneously.
Liam Kelly
executiveWhat's great about pursuing a BLA submission, Larry, is that it opens up the civilian and military markets alike. We begin with the military in 2021, no question, since as you're aware they assisted us in developing the product, and a typical BLA submission takes 9 months—roughly—and we're on a fast track. The FDA never informs you when that fast track concludes, and out of caution, we've built in remarkably modest revenue during this year's 4th quarter for this product, and we fully expect it to ramp in 2022. To address your point about the cadence, it's a $100 million market. The military portion is $25, so during 2022 we'll concentrate on that military segment, and I consistently warn investors not to anticipate the military placing a $10 million order immediately. It would be substantially, substantially lower than that, but as we grow the market and as they introduce it via special ops, via the CEOs into the broader military, we can then shift toward the civilian market. And in fact the largest slice of the civilian market, Larry, is air ambulances, given the space constraints and how well EZPlas adapts to that setting, and that was also rather encouraging when we reexamined this market—that it's essentially two major segments, with the remainder being smaller. That makes it simpler for us to concentrate. So that's our view of how it ramps as we move through '21 and into '22.
Larry Keusch
analystAll right, that's great. Thank you, everyone. I appreciate it.
Liam Kelly
executiveThank you, Larry.
Shagun Singh
analystThanks a lot for fielding this. Two things — first about the outlook, then about Manta. On the outlook, could you tell us what backlog assumption sits inside it? By our calculation, that might be roughly 9% of sales. I'm certain part of it could carry into 2022 and beyond. Then on Manta, would you address the litigation Essential Medical brought concerning the sales milestone that was missed and the payment from Teleflex after the merger? Anything you can offer regarding where you stand, how large that milestone payment is, and what happens next to get it resolved. Thanks for answering.
Liam Kelly
executiveSure, of course. Let me take the outlook question first. When we talk about our overall revenue guidance of 10% to 11.5%, what's baked into that is an assumption that COVID conditions improve relative to last year — but it doesn't assume a backlog or a sudden surge of procedures coming back on top of that during the second half. Honestly, Shagun, figuring out what that backlog will actually look like is really difficult for us, and it's just as difficult to determine whether hospitals will even have the capacity to work through it. As things start to recover, my view on how it plays out geographically hasn't changed much. I still think the Americas and Asia are going to be the ones leading the way. In my view, Europe is definitely going to trail behind. It plays a role in the healthcare system, and the pace at which they're currently distributing the vaccine just doesn't look as forceful as what we're seeing elsewhere around the globe. Regarding the Essential Medical losses you brought up — absolutely, we're well aware of them, and we feel sure we've done the right thing. Honestly, we think that lawsuit has no merit. We plan to fight it hard. And Shagun, you know the Manta product well, and you know we've put a lot behind it, in terms of clinical evidence as well as sales and marketing resources. This product really matters for Teleflex's revenue, and it came through strongly even while the pandemic was going on — it expanded by more than 30% worldwide during 2020, and in the important North American market it grew by nearly 90%. Our goal for this year is to keep converting roughly 8% of that big core market. Now, on the question about milestones: there are contingent payment milestones built into our financials, and the overall milestone amount is what this dispute is about. Still, like I said, we intend to fight it quite vigorously. Shagun?
Shagun Singh
analystI really appreciate it. I have everything I need.
Liam Kelly
executiveAll right, thank you.
Matt Taylor
analystHey everyone, I appreciate you taking my question. The first thing I'd like to ask about is that with the UroLift launch in Japan approaching, you've shared a few high-level details regarding the TAM and the count of urologists and so on. I was hoping you might get a bit more specific about what's within your control during the rollout, such as how fast training happens, particularly since we're still dealing with a bit of a COVID situation—how soon should we expect that adoption, considering the limits created by where you're focusing your investment?
Liam Kelly
executiveMatt, here's what we've done: we already went into Japan ahead of the market with market development specialists, and we keep engaging. We've pinpointed the top 20 urologists. Before COVID, we actually brought a U.S. physician who speaks Japanese into the country to conduct some peer-to-peer training. We also held a virtual BPH Summit that included a number of those 20 Japanese urologists. It ended up being like Reagan's trickle-down economics, except here it's trickle-down urologists in Japan—we train those at the top of the tree, and these 20 are the key ones we've identified so we can then extend it out to the remaining urology practices, and as part of our reimbursement we're required to do a mandated collection of data. So we'll handle that during the fourth quarter to collect that information, and we're genuinely excited—plus another element within our control, Matt, is bringing on more sales reps. Now, when we look at the timing, it's going to line up really, really nicely for us, because Japan is another America in that they're handling the buyers quite well at this point and they're beginning to roll out the vaccine. So we believe that as we move into Q3 and Q4, we'll be needing access in order to train. We think the timing will work out quite well for us and give us fairly broad access to the people we want to train. So we've done a pretty solid job on the groundwork so far, and we feel quite good about identifying the urologists we need to train, and there's a heightened level of knowledge regarding the UroLift because many of these Japanese urologists are closely connected to the U.S. Urology Association; so there's heightened awareness of the product's availability and a desire to get access to it. And once reimbursement is in place, I believe that's when we'll truly start ramping up our efforts.
Matt Taylor
analystThanks. One more quick question as we look ahead over the coming 2 years: should we expect the same rate of urologist training in Japan as in the U.S., roughly a couple hundred annually? Could you describe those intermediate-term plans?
Liam Kelly
executiveSure. Keep in mind that the number of urologists is not large. So it stands to reason that the figure will be somewhat lower, plus the market there is somewhat smaller; and urology practice in Japan includes subspecialties. So, out of those 9,000 urologists, you'd figure roughly 5,000 fall within the specialty we're targeting. That's under half of the comparable figure in the U.S. So keep that in mind regarding the pace, but given those numbers, my expectation would be a comparable pace, so if 400 to 500 get trained in the U.S., you'd expect to train half that amount once Japan ramps up.
Matt Taylor
analystAll right, that makes sense. That's great, thanks.
Liam Kelly
executiveThanks.
Analyst
analystHello, this is Erin, calling in on behalf of Rich. Just one quick question. You folks possibly said that M&A would be the primary area for putting capital to work. I was curious whether you might give us some detail about which sorts of areas you're targeting, and also, should we be looking for bigger transactions, or the usual small bolt-ons?
Liam Kelly
executiveErin, to begin with, like Tom mentioned during that commentary, our 4th quarter was outstanding when it comes to producing cash and bringing debt down; as a result, we're once again under 3 times on a net leverage basis. Regarding the kinds of assets, to start, the strategic piece of how we approach M&A, the assets that suit one of our current channel portfolios sit in the alliance space. For instance, we genuinely favor the cath lab. So, were we to expand into neurovascular or peripheral vascular in that same call point, that would be an appealing possibility. We're also drawn to technology possessing IP, such as Z-Medica, which we recently closed, with IP lasting through 2033; therefore, that's, we prefer to safeguard the businesses. We seek assets with a portfolio of clinically differentiated products; we seek assets that generate value in healthcare economics or synergies along those lines. We also seek products that are sticky, and by sticky we mean ones that get utilized repeatedly, over and over, within the Interventional space, the Vascular space, the anesthesia emergency medicine space, the men's health space and the surgical space, so I believe that's what's great about Teleflex, we're examining a wide range of areas, which is why we identify these assets, and additionally we're extremely disciplined in how we go about it, and you should count on us staying disciplined. I can say that our pipeline remains quite full in this environment, even with COVID around. It astonishes me how much work we manage to accomplish, and we closed Z-Medica while COVID was ongoing, and at present we're under 3 and that figure would drop even more as this year progresses. So, we possess firepower, we're constantly searching, and we keep searching at this very moment.
Analyst
analystAlright, excellent stuff. Then I've got one more quick question about Manta. You said it was up more than 30%. Could you perhaps walk us through a few of the trends you're observing for that specific product of ours, and then maybe what we should expect during 2021?
Liam Kelly
executiveSure — looking back at 2020, our conversion came in at slightly above 5% of the market, and for 2021 we're looking at converting roughly 8% of the market. That's the pace we're on — and that's happening in the middle of COVID; however, what I'd say about the trends is that adoption has been fairly heavy in TAVR procedures — close to 90% of our cases right now are still performed in TAVR, and that's the space we're concentrating on; it's a market opportunity worth $200 to $300 million, and we keep ramping it up, we keep sales resources assigned to it, and we're also intending to run some clinical work on the product, plus there are certain enhancements we'd like to make to it so it's even better than it is right now. So overall, the progress we're seeing has us genuinely encouraged, and we anticipate continuing to make progress this year and on into the following year — this is going to be a multi-multi-year growth driver for Teleflex, and as we convert that market, there's a long runway in front of us to convert.
Analyst
analystGreat, thanks so much.
Liam Kelly
executiveThanks, Erin.
Anthony Petrone
analystThank you. I've got a pair regarding UroLift, and after that one about Z-Medica. Regarding UroLift, I'm simply attempting to grasp how large the total accumulation is getting. Liam, COVID continues to circulate, so that remains a strain, and on the demand side you've got DTC, so I'm curious whether you could put a figure on the pile-up of procedures? Then, thinking about the last few quarters, is there anything worth flagging about competition—are you noticing anything notable from the other devices on the market? Then I'll ask something else.
Liam Kelly
executiveRight, so to begin with your question about the backlog; during quarter 4, we began—you might see this noted within how we measured the COVID effect, Anthony, just so it's clear, in measuring the COVID effect, the subsequent COVID, it rose by 335%, and within that our procedures exceeded the base rate figure for the prior year, 2019. Thus, quarter 4 cancellations beyond that base rate, if you assigned a dollar figure, come to roughly $4 million; that should give you some sense of that backlog, since those cancelled procedures ought to return at some point once things open up, and those were procedures that had been scheduled—the patient was set to undergo the UroLift procedure, and then either the day before or the very day, they called it off, presumably because of COVID worries; so that's the strongest yardstick I can offer on that. What else did you ask? Anthony, my apologies.
Anthony Petrone
analystThe second item concerned competition — has anything noteworthy come to your attention out there?
Liam Kelly
executiveThere is genuinely nothing to report. The marketplace still contains the same rivals. What I can say is that we have now gone past the 250,000 patient mark for those treated with the UroLift, which represents a significant milestone for us. Another significant milestone involved an all-time high revenue during the 4th quarter. That revenue had never been reached by us, and achieving it while a rising COVID pandemic made the situation much worse strikes me as very encouraging. So, Anthony, there is nothing new to report on the competitive front.
Anthony Petrone
analystThen for the follow-ups, one would be about UroLift once more — could you remind us regarding medical management, the study that was referenced today, how many patients do you actually believe might move over to UroLift among the medical — those who are on medical management right now? And then regarding Z-Medica there are 3 verticals: trauma, EMS and Interventional — where do you expect the greatest synergies on the revenue line, given the existing Teleflex infrastructure? Thanks.
Liam Kelly
executiveSo, first regarding your UroLift. The quantity of men receiving medical therapy equals the total 12 million men in America, 1.5 million among them have quit the medical therapy, and that represents our target market of 6 billion, yet there are a further 7 million men in America who are taking the drug therapy. So, it's a much larger market, and that moves the addressable TAM from $6 billion to $30 billion if we could draw in all of those individuals too; so, that will show you the scale of the size; as for your question about the synergies, that's where we'll be capable of leveraging Z-Medica from a call point; certainly, the military and EMS call point is a very strong call point for us, and Z-Medical possesses an exceptionally strong trauma call point. So, the synergies between the 2 companies are excellent in the strength of the call point they now have. And then just bear in mind, Anthony, that we have EZPlas, which we just submitted from a BLA coming down the PICC behind that really strong sales channel; so, that's a business with enthusiasm and we're quite encouraged about what we can do in that space.
Anthony Petrone
analystThanks once more.
Matthew O'Brien
analystMorning, and I appreciate you taking our questions. So, Liam, I believe what's going to grab most folks' attention today is the '21 revenue guidance once Z-Medica is excluded. That's roughly 6.5% to 8% growth measured in constant currency, with easier comparables, and I realize there's still some COVID effect. Could you unpack a bit what you anticipate on the volume side this year, and where that sits below the trend line relative to what people expect from Teleflex in terms of organic growth rate, or are there other spots where you're attempting to be—I know you're attempting to be cautious, but more cautious than elsewhere—it appears UroLift could be one of those spots; any sort of color on the organic guidance you gave for the full year would be useful.
Liam Kelly
executiveMatt, many thanks for that question, and really it boils down to when you presume you will observe recovery from COVID. Well, we might have been more aggressive with our guidance and presumed we would start to observe recovery from COVID in Q2. I don't believe it has anything to do with volume against price, against all the other elements, Matt, frankly, it's entirely about COVID and it's entirely about the presumption you make regarding COVID. So, were we to be more aggressive and were we to presume we're going to observe a recovery in Q2, as I've heard from certain peers that they have, I believe, it would be a stronger revenue story and consequently a stronger earning story. As I mentioned in response to the question, I think David posed—we've attempted to be somewhat more prudent and maybe somewhat more cautious. We still see it's going to be rather choppy as you move through Q1 and Q2; and remember the COVID cases in January and early February were far worse than in December and late November. And so that's the limiting factor, Matt, is your presumption about when COVID is going to recover; and if you examine it and occasionally people want to return to 2019 and if you examine the back half of 2019, contrasted with 2021 we're back within that normal, long-term guidance range for Teleflex in the back half '21 versus '19 and once more it's entirely about the presumption—if you presume you're going to recover in Q2 and be aggressive, your revenues is greater. Should you take the second half of the year into account, your revenue will come in somewhat lower, though a degree of caution has been factored in, and clearly we will bring the investment community up to date when we reach our Q2 earnings release regarding what we have observed during that quarter, and should it prove better, that benefits investors, is excellent for Teleflex, and so forth.
Matthew O'Brien
analystUnderstood, and for my next question, I'll shift away from the main subject a bit. I realize there are plenty of inquiries regarding NeoTract and Manta and that category, but it appears you're allocating a substantial sum toward MDR—roughly $10 million dollars during this year. I'm aware of your current U.S. situation, yet I'm simply wondering whether that expenditure means OUS growth might represent a possible source of upside, given that competitors are unable to commit as heavily or be as ready as you are, as we move into '22, '23 and '24, purely from a strategic standpoint considering all the investments being made on the MDR front. Could that be somewhere that catches some people off guard in terms of the upside over the next couple of years?
Liam Kelly
executiveWell, Matt, I believe what you may observe occurring is that MDR's demands place a considerable weight on certain companies, and what you could witness is that it weighs especially heavily on smaller firms; at present, many smaller med-tech businesses exist throughout Europe that I believe will find it difficult to keep meeting MDR requirements, and they must satisfy identical standards, quite understandably, as a bigger organization such as Teleflex. Therefore, 2 outcomes are going to occur. My guess is those people will either choose that they no longer wish to remain in that specific space, which opens up possibilities for bigger corporations, or consolidations plus M&A chances will emerge to purchase some of those smaller European entities. And as you're aware, Teleflex acquires companies regularly, and we'll aim to seize those chances whenever they present themselves.
Matthew O'Brien
analystAppreciate it.
Matthew Mishan
analystExcellent. And we appreciate your time in answering our questions.
Liam Kelly
executiveHello there, Mark.
Matthew Mishan
analystLiam, I want to focus on EZPlas. Could you give us some background on how complicated the BLA for EZPlas is, why it required multiple years to complete, and what you've resolved with the FDA that makes you confident about approval within a reasonable timeframe? Then, as a follow-up about Z-Medica and EZPlas, would they use the same sales team, and how are you planning to scale up that sales effort?
Liam Kelly
executiveYes, absolutely. So, first of all I'll answer the last part of the first. Matt, they're going to be part of one combined team. What we're doing is merging the Z-Medica and Teleflex sales organizations, and that creates a chance for us to field a much more powerful sales force in this channel, which should help us speed up growth for Z-Medica, Vidacare, and EZPlas once it's on the market. As for how long the BLA submission took, Matt, the real reason is that this was new ground for the FDA as well as for Teleflex. A biologic like this had never been cleared by the FDA before. So for both them and us, it was unexplored territory. So it took them a good while to finish their review, since we were supplying them with information piece by piece. To be fair, they collaborated with us and let us send in partial data as part of the BLA submission. That meant we could hand over some information, receive feedback, hand over additional information, receive more feedback, and eventually complete the submission in January. As for my reasoning that it ought to take under nine months — first, we have fast track status, and second, they had already reviewed all the clinical data and provided their feedback on it. Before we filed the final BLA submission, we had already provided them with a substantial bolus of data. So they've received quite a lot of data from us. That should therefore assist them in their assessment, and they've also been extremely cooperative in working alongside us and the military to move this through the BLA submission. So all of those considerations would leave me feeling quite encouraged about a reasonable timeframe, under the nine months, for getting this approved. Excellent. Thank you. Your next question comes from Mike Matson with Needham & Company.
Mike Matson
analystMorning, and thanks for taking my questions.
Liam Kelly
executiveHello there, Mike.
Mike Matson
analystI want to ask about EZPlas. I realize plenty of people are focused on the BLA and what the U.S. opportunity looks like, but does this product have any potential internationally?
Liam Kelly
executiveYes, Mike, it does. At present, within the military, out of 25 million, most of that sits in the U.S., yet some share is abroad, and naturally the civilian market figure is worldwide. So of that 100 million in needs, it's a global figure rather than one limited to the U.S., and the same standards apply overseas as well: air ambulances and the military. However, as nearly everyone knows, the U.S. military ranks among the most active and biggest military forces in the world, so it accounts for a substantial share of that $25 million addressable market.
Mike Matson
analystAll right, understood. Next, I'd like to ask about the PICC business. It used to draw plenty of focus, but with some of the more recent growth drivers, it hasn't received as much, so are you still gaining share in that market? Have competitive dynamics shifted at all in that area?
Liam Kelly
executiveWell, I'm happy to say — and I believe I touched on this during my opening remarks — that our PICC business expanded by nearly 20% during the quarter, Mike. So we keep gaining share, and we remain very deliberate about how we expand that business, thanks to our coating technology, which enables us to win share away from rivals in that space; and within just a brief span of three years, we've gone from holding the number three position to holding the number two position, and we keep growing that area aggressively.
Mike Matson
analystAll right, appreciate it.
Jake Elguicze
executiveThanks, operator. And thanks to all of you for being with us today. That brings the Teleflex Incorporated fourth quarter of 2020 Earnings Conference Call to a close. Enjoy the rest of your day.
Operator
operatorThat brings us to the end of today’s conference call, everyone. We appreciate your participation. You’re welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.